MGeND: an integrated database for Japanese clinical and genomic information

MGeND: an integrated database for Japanese clinical and genomic information

Human Genome Variation volume 6, Article number: 53 (2019)

Abstract To promote the implementation of genomic medicine, we developed an integrated database, the Medical Genomics Japan Variant Database (MGeND). In its first release, MGeND provides data regarding genomic variations in Japanese individuals, collected by research groups in five disease fields. These variations consist of curated SNV/INDEL variants and susceptibility variants for diseases established by […]

Key Observations on GDPR

Key Observations on GDPR

A period of sheer panic as companies realized the mountain they needed to climb towards compliance.

The General Data Protection Regulation (GDPR) came into effect on May 25, 2018, with its objectives being to reshape the relationship between organizations and individuals, reform the approach to how businesses handle personal data and to rehabilitate (sanction) organizations which fail to comply. The run-up to May 25, 2018, maybe neatly summarized as a period […]

Gene therapy coming of age: Opportunities and challenges to getting ahead                                          | Mckinsey & Compamy

Gene therapy coming of age: Opportunities and challenges to getting ahead | Mckinsey & Compamy

Amid breakthroughs in gene editing, the pharma industry must recalibrate its development and reimbursement model for therapies that go beyond the traditional approach to disease treatment.

The completion of the first draft of the human genome in 2001 was supposed to kick off an era of personalized medicine and curative gene therapies.1 Only in the past few years has that promise started to become reality: several RNA- and DNA-based therapies are now on market, and the first curative gene therapy, Luxturna, was approved […]

Genetic testing: Opportunities to unlock value in precision medicine | Mckinsey & Company

Genetic testing: Opportunities to unlock value in precision medicine | Mckinsey & Company

Winning diagnostics companies will integrate advanced analysis of genomic data with other data sets and electronic medical records, as well as effective reimbursement strategies.

With a growing repository of personalized data at the molecular level, molecular-diagnostics companies are uniquely positioned to unlock value. The global market for personalized medicine has grown rapidly since the inception of the Precision Medicine Initiative, announced by Barack Obama during his 2015 State of the Union address. Market research estimated the 2016 global market […]

Load more